FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for initiating, enhancing or prolongating an antitumor response; it can be used in medicine. The method includes the injection of an immune control point modulator after 12-96 hours after the first injection of a multifunctional antibody redirecting T-cells.
EFFECT: method can be used in the effective combination therapy of cancer.
39 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| COMBINATION OF IMMUNE CHECKPOINT MODULATOR AND COMPLEX CONTAINING CELL-PENETRATING PEPTIDE, CARGO MOLECULE, AND TLR PEPTIDE AGONIST FOR MEDICAL USE | 2017 |
|
RU2748378C2 |
| COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX CONTAINING A CELL-PENETRATING PEPTIDE, A CARGO MOLECULE, AND A TLR PEPTIDE AGONIST, FOR APPLICATION IN MEDICINE | 2017 |
|
RU2769314C1 |
| METHODS AND ANTIBODIES FOR IMMUNE RESPONSE MODULATION | 2016 |
|
RU2757489C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
